Navigation Links
More Than Half of Patients Treated for Benign Prostatic Hyperplasia Receive Boehringer Ingelheim's Flomax as First-Line Therapy
Date:4/7/2008

Less Than 20 Percent of Patients Diagnosed with the Disease Receive Pharmacotherapy Within a Year of Their Diagnosis, According to a New Report

From Decision Resources

WALTHAM, Mass., April 7, 2008 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Boehringer Ingelheim's Flomax, also marketed as Astellas's Harnal in Japan, is the physician's drug of choice for newly diagnosed benign prostatic hyperplasia patients. Garnering more patient share than any other alpha blocker in first- and second-line therapy for benign prostatic hyperplasia, Flomax holds a 55.2 percent first-line patient share, compared with 12.4 percent for Sanofi-Aventis's Uroxatral, 4.8 percent for doxazosin (Pfizer's Cardura/Cardura XL, generics), and 4.3 percent for terazosin (Abbott's Hytrin, generics).

"Flomax stands out among alpha blockers thanks to its lower propensity to induce orthostatic hypotension, despite evidence of a high incidence of retrograde ejaculation and higher cost relative to generic agents in this class", said Nathan Calloway, analyst at Decision Resources. "However, rather than calling attention to Flomax's side-effect/safety profile, the highest proportion of urologists we surveyed (83 percent) rank familiarity with the drug as an important reason to choose Flomax over Uroxatral, whereas the largest percentage of primary care physicians (66 percent) believe that Flomax's reimbursement and formulary position is a key advantage over Uroxatral's."

The report entitled Treatment Algorithms in Benign Prostatic Hyperplasia also finds that slightly less than one-fifth (18.9 percent) of newly diagnosed benign prostatic hyperplasia patients receive pharmacological treatment within one year of their initial diagnosis. Primary care physicians and urologists surveyed suggest that patient reluctance to take drugs that are associated with sid
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
5. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
8. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
9. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
10. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
11. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... On Wednesday of last week RENU 28, the ... molecules, became available for purchase in Australia and New Zealand, ... RENU 28 works is, if you think about the definition ... of cellular renewal within your body. If you think about ... of cellular renewal. What RENU 28 does is it works ...
(Date:8/20/2014)... first time, chemists have succeeded in measuring vibrational motion ... The study reveals how vibration of a single molecule ... , The study was performed at the University of ... University of Jyvskyl works as a visiting fellow under ... study. The second team was lead by Professor Eric ...
(Date:8/20/2014)... , Aug. 20, 2014  PAREXEL International Corporation ... will be presenting at the Baird Healthcare Conference in ... and Chief Financial Officer, will be making a presentation ... EDT on Wednesday, Sept. 3, 2014. A ... the "Investors" section of PAREXEL,s website at www.PAREXEL.com ...
(Date:8/20/2014)... the health of your heart, researchers have discovered. , ... standard TENS machine like those designed to relieve labour ... small raised flap at the front of the ear ... stimulation changed the influence of the nervous system on ... drive failing hearts too hard. , Professor Jim Deuchars, ...
Breaking Biology Technology:RENU 28 Skin Care Now Available in Australia and New Zealand 2Seeing a molecule breathe 2PAREXEL International To Present At Baird Healthcare Conference 2'Tickling' your ear could be good for your heart 2
... Dendreon Corporation (Nasdaq: DNDN ) today announced ... reviewed the impact of labeled and unlabeled use of ... advanced prostate cancer. This panel was convened as a ... initiated by the Centers for Medicare and Medicaid Services ...
... Nov. 17, 2010 Terso Solutions, Inc. ... cost way to control inventory management ... that can be implemented in less ... http://photos.prnewswire.com/prnh/20101117/CG03241-a ) (Photo:   http://www.newscom.com/cgi-bin/prnh/20101117/CG03241-a ...
... RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2010 Chimerix, ... presented an update to the World Health Organization (WHO) ... CMX001, at the 12th Meeting of the WHO Advisory ... "Status of CMX001 for Smallpox and Other dsDNA Viruses." ...
Cached Biology Technology:Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence 2Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence 3Terso Solutions RFID Jump Start Takes the Risk Out of Implementing RFID for Hospitals and Research Laboratories Looking to Streamline Operations and Improve Regulatory Compliance 2Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research 2Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research 3
(Date:8/20/2014)... this image of the Para and Mato Grosso states ... intentionally set in order to deforest the land. Deforestation ... trees where the land is thereafter converted to a ... to farms, ranches, or urban use. The herringbone-patterned tan ... Rainforest in the middle of the image are evidence ...
(Date:8/20/2014)... Oklahoma Medical Research Foundation a five-year, $14.5 million grant ... effects on humans. , For 10 years, OMRF ... the human immune response to anthrax bacteria as part ... funding came soon after anthrax-laced letters killed five and ... of Sept. 11, 2001. , The long-term goal ...
(Date:8/20/2014)... aroma of sunscreen and seawater signals a relaxing trip ... the idyllic beach vacation comes with an environmental hitch. ... the sea, they can become toxic to some of ... for many other marine animals. Their study appears in ... , Antonio Tovar-Sanchez and David Snchez-Quiles point out that ...
Breaking Biology News(10 mins):$14.5 million grant awarded to continue anthrax studies 2
... may be one step closer to a ,recipe, for large-scale ... Induced pluripotent stem cells (iPSCs) can be of great ... many different types of cells. However, producing these cells is ... unknown. But researchers from the University of Toronto, the ...
... today in the journal Gondwana Research , has ... Indian tectonic plates, demonstrating how they formed the supercontinent ... Holloway University, The Australian National University and Geoscience Australia, ... plates evolved and where they should be positioned when ...
... that crabs may have disappeared from Antarctica only to return ... ago following the discovery of a major colony of King ... continental shelf off the Antarctic Peninsula. It was thought ... 15 million years ago and was returning as seawater temperatures ...
Cached Biology News:Toronto team ID proteins key in stem cell production 2Evidence suggests Antarctic crabs could be native 2
... ( Abpromise for all tested applications). ... to amino acids 14/26 of Mouse Green cones ... acids 18/30 of tiger red cones opsin 1 ... Entrez Gene ID: 5956 ...
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Request Info...
Myt 1 (N-17)...
Biology Products: